Based on our findings, LIR‐1 marks a unique subset among expanded NK cells that has the intrinsic potential to reject cells that have lost HLA class I because of tumor transformation, while efficiently and selectively targeting HLA class I+ cells via tumor‐targeting antibodies. The gene discussed is LILRB1; the disease is neoplasm.